- Home
- INTS vs PMN Comparison
INTS vs PMN Comparison
Compare INTS & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- PMN
- Stock Information
- Founded
- INTS 2012
- PMN 2004
- Country
- INTS United States
- PMN Canada
- Employees
- INTS N/A
- PMN N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- PMN Pharmaceuticals and Biotechnology
- Sector
- INTS Health Care
- PMN Health Care
- Exchange
- INTS Nasdaq
- PMN Nasdaq
- Market Cap
- INTS 9.4M
- PMN 17.0M
- IPO Year
- INTS 2023
- PMN N/A
- Fundamental
- Price
- INTS $0.30
- PMN $0.45
- Analyst Decision
- INTS Strong Buy
- PMN Strong Buy
- Analyst Count
- INTS 3
- PMN 2
- Target Price
- INTS $8.50
- PMN $4.50
- AVG Volume (30 Days)
- INTS 2.4M
- PMN 37.1K
- Earning Date
- INTS 08-07-2025
- PMN 08-07-2025
- Dividend Yield
- INTS N/A
- PMN N/A
- EPS Growth
- INTS N/A
- PMN N/A
- EPS
- INTS N/A
- PMN N/A
- Revenue
- INTS N/A
- PMN N/A
- Revenue This Year
- INTS N/A
- PMN N/A
- Revenue Next Year
- INTS N/A
- PMN N/A
- P/E Ratio
- INTS N/A
- PMN N/A
- Revenue Growth
- INTS N/A
- PMN N/A
- 52 Week Low
- INTS $0.26
- PMN $0.46
- 52 Week High
- INTS $5.10
- PMN $2.37
- Technical
- Relative Strength Index (RSI)
- INTS 37.20
- PMN 36.88
- Support Level
- INTS $0.29
- PMN $0.48
- Resistance Level
- INTS $0.35
- PMN $0.50
- Average True Range (ATR)
- INTS 0.04
- PMN 0.03
- MACD
- INTS 0.02
- PMN -0.00
- Stochastic Oscillator
- INTS 38.83
- PMN 1.56
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.